100s of titles, one news app for just $10 a month.
Dive Deeper:
Get all your news in one place
Latest Business news:
Meta asks to be spared tighter rules in Australia, saying iPhone’s tracking blocker is hurting business
Company tells consumer watchdog it is set to lose $10bn this year in wake of Apple iOS feature hampering ability…
Read news from The Economist, FT, Bloomberg and more, with one subscription
Learn More
Business investment expected to pick up
Economists expect figures will show business investment picked up further in the March quarter, providing a boost to growth in…
Woolworths brings in more cameras amid suspected rise in shoplifting
Supermarket giant Woolworths has installed cameras above self-service checkouts at select stores amid fears about a rise in shoplifting.
Super co-contribution has cost $10 billion to help the wrong Australians – so let's scrap it
Concerned that many people won’t have enough retirement savings even with compulsory superannuation, since 2003 the Australian government has had…
Terra Blockchain to Split, Abandon Collapsed UST Stablecoin
A proposal by the founder of the troubled Terra ecosystem to salvage the project was approved, averting a total collapse…
From analysis to good news, read the world’s best news in one place
Jack Dorsey leaves Twitter's board of directors
Dorsey signaled his plans last fall.
Google Takes Yet Another Run at E-Commerce—and Amazon
The search giant abandoned plans to mimic the Seattle-based leviathan and has reset its shopping strategy around search and ads.

Earnings Preview For KemPharm

By Benzinga Insights

KemPharm (NASDAQ:KMPH) is set to give its latest quarterly earnings report on Thursday, 2022-05-12. Here's what investors need to know before the announcement.

Analysts estimate that KemPharm will report an earnings per share (EPS) of $-0.05.

KemPharm bulls will hope to hear the company to announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Historical Earnings Performance

Last quarter the company missed EPS by $0.01, which was followed by a 5.45% drop in the share price the next day.

Here's a look at KemPharm's past performance and the resulting price change:

Quarter Q4 2021 Q3 2021 Q2 2021 Q1 2021
EPS Estimate -0.07 -0.07 0.22 -0.17
EPS Actual -0.08 -0.06 -0.40 -1.61
Price Change % -5.45% 2.86% -10.7% 6.92%

Stock Performance

Shares of KemPharm were trading at $4.35 as of May 10. Over the last 52-week period, shares are down 52.76%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release.

To track all earnings releases for KemPharm visit their earnings calendar on our site.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

What is inkl?
The world’s most important news, from 100+ trusted global sources, in one place.
Morning Edition
Your daily
news overview

Morning Edition ensures you start your day well informed.

No paywalls, no clickbait, no ads
Enjoy beautiful reading

Content is only half the story. The world's best news experience is free from distraction: ad-free, clickbait-free, and beautifully designed.

Expert Curation
The news you need to know

Stories are ranked by proprietary algorithms based on importance and curated by real news journalists to ensure that you receive the most important stories as they break.